Effects of sleep disturbances and circadian rhythms modifications on cognition in breast cancer women before and after adjuvant chemotherapy: the ICANSLEEP-1 protocol.
Adjuvant chemotherapy
Breast cancer
Circadian rhythms
Cognition
Sleep structure
White matter integrity
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
01 Dec 2023
01 Dec 2023
Historique:
received:
05
07
2023
accepted:
21
11
2023
medline:
4
12
2023
pubmed:
2
12
2023
entrez:
1
12
2023
Statut:
epublish
Résumé
Many patients treated for breast cancer (BC) complain about cognitive difficulties affecting their daily lives. Recently, sleep disturbances and circadian rhythm disruptions have been brought to the fore as potential contributors to cognitive difficulties in patients with BC. Yet, studies on these factors as well as their neural correlates are scarce. The purpose of the ICANSLEEP-1 (Impact of SLEEP disturbances in CANcer) study is to characterize sleep using polysomnography and its relationship with the evolution of cognitive functioning at both the behavioral and the neuroanatomical levels across treatment in BC patients treated or not with adjuvant chemotherapy. ICANSLEEP-1 is a longitudinal study including BC patients treated with adjuvant chemotherapy (n = 25) or not treated with adjuvant chemotherapy (n = 25) and healthy controls with no history of BC (n = 25) matched for age (45-65 years old) and education level. The evaluations will take place within 6 weeks after inclusion, before the initiation of chemotherapy (for BC patients who are candidates for chemotherapy) or before the first fraction of radiotherapy (for BC patients with no indication for chemotherapy) and 6 months later (corresponding to 2 weeks after the end of chemotherapy). Episodic memory, executive functions, psychological factors, and quality of life will be assessed with validated neuropsychological tests and self-questionnaires. Sleep quantity and quality will be assessed with polysomnography and circadian rhythms with both actigraphy and saliva cortisol. Grey and white matter volumes, as well as white matter microstructural integrity, will be compared across time between patients and controls and will serve to further investigate the relationship between sleep disturbances and cognitive decline. Our results will help patients and clinicians to better understand sleep disturbances in BC and their relationship with cognitive functioning across treatment. This will aid the identification of more appropriate sleep therapeutic approaches adapted to BC patients. Improving sleep in BC would eventually help limit cognitive deficits and thus improve quality of life during and after treatments. NCT05414357, registered June 10, 2022. Version 1.2 dated March 23, 2022.
Sections du résumé
BACKGROUND
BACKGROUND
Many patients treated for breast cancer (BC) complain about cognitive difficulties affecting their daily lives. Recently, sleep disturbances and circadian rhythm disruptions have been brought to the fore as potential contributors to cognitive difficulties in patients with BC. Yet, studies on these factors as well as their neural correlates are scarce. The purpose of the ICANSLEEP-1 (Impact of SLEEP disturbances in CANcer) study is to characterize sleep using polysomnography and its relationship with the evolution of cognitive functioning at both the behavioral and the neuroanatomical levels across treatment in BC patients treated or not with adjuvant chemotherapy.
METHODS
METHODS
ICANSLEEP-1 is a longitudinal study including BC patients treated with adjuvant chemotherapy (n = 25) or not treated with adjuvant chemotherapy (n = 25) and healthy controls with no history of BC (n = 25) matched for age (45-65 years old) and education level. The evaluations will take place within 6 weeks after inclusion, before the initiation of chemotherapy (for BC patients who are candidates for chemotherapy) or before the first fraction of radiotherapy (for BC patients with no indication for chemotherapy) and 6 months later (corresponding to 2 weeks after the end of chemotherapy). Episodic memory, executive functions, psychological factors, and quality of life will be assessed with validated neuropsychological tests and self-questionnaires. Sleep quantity and quality will be assessed with polysomnography and circadian rhythms with both actigraphy and saliva cortisol. Grey and white matter volumes, as well as white matter microstructural integrity, will be compared across time between patients and controls and will serve to further investigate the relationship between sleep disturbances and cognitive decline.
DISCUSSION
CONCLUSIONS
Our results will help patients and clinicians to better understand sleep disturbances in BC and their relationship with cognitive functioning across treatment. This will aid the identification of more appropriate sleep therapeutic approaches adapted to BC patients. Improving sleep in BC would eventually help limit cognitive deficits and thus improve quality of life during and after treatments.
TRIAL REGISTRATION
BACKGROUND
NCT05414357, registered June 10, 2022.
PROTOCOL VERSION
METHODS
Version 1.2 dated March 23, 2022.
Identifiants
pubmed: 38041077
doi: 10.1186/s12885-023-11664-x
pii: 10.1186/s12885-023-11664-x
pmc: PMC10693085
doi:
Banques de données
ClinicalTrials.gov
['NCT05414357']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1178Subventions
Organisme : Université de Caen Normandie
ID : Doctoral Contract
Organisme : Région Normandie
ID : Chair of excellence 2020
Organisme : Fondation ARC pour la Recherche sur le Cancer
ID : ARCPJA2021060003783
Informations de copyright
© 2023. The Author(s).
Références
World J Biol Psychiatry. 2010 Jun;11 Suppl 1:16-21
pubmed: 20509828
Cancer. 2004 Aug 1;101(3):466-75
pubmed: 15274059
Front Neurosci. 2022 Sep 07;16:908268
pubmed: 36161169
J Cancer Surviv. 2009 Dec;3(4):223-32
pubmed: 19760150
J Psychosom Res. 1995 Apr;39(3):315-25
pubmed: 7636775
Sci Rep. 2022 Feb 15;12(1):2557
pubmed: 35169245
Breast Cancer Res Treat. 2012 Apr;132(3):1099-106
pubmed: 22205140
Arch Gen Psychiatry. 1961 Jun;4:561-71
pubmed: 13688369
J Clin Oncol. 2012 Jan 20;30(3):274-81
pubmed: 22184379
J Pain Symptom Manage. 2007 Apr;33(4):398-409
pubmed: 17397701
J Clin Oncol. 1993 May;11(5):997-1004
pubmed: 8487063
JNCI Cancer Spectr. 2019 Jun 07;3(3):pkz041
pubmed: 31355357
Cancer Med. 2019 May;8(5):2654-2663
pubmed: 30884207
J Neurosci. 2013 Jan 2;33(1):227-33
pubmed: 23283336
Neuropsychol Rev. 2022 Sep;32(3):483-505
pubmed: 34355305
BMC Cancer. 2022 Dec 13;22(1):1308
pubmed: 36513991
BMJ Open. 2019 Oct 7;9(10):e032265
pubmed: 31594904
Psychiatry Res. 1989 May;28(2):193-213
pubmed: 2748771
Ann Oncol. 2019 Dec 1;30(12):1925-1940
pubmed: 31617564
Nat Rev Neurosci. 2010 Feb;11(2):114-26
pubmed: 20046194
Psychol Aging. 2014 Sep;29(3):658-65
pubmed: 25244484
J Psychosom Res. 2019 Sep;124:109746
pubmed: 31443811
Neuron. 2017 Apr 5;94(1):19-36
pubmed: 28384471
Int J Cancer. 2021 Apr 5;:
pubmed: 33818764
Palliat Support Care. 2018 Jun;16(3):325-334
pubmed: 28508735
Chronobiol Int. 2019 Aug;36(8):1156-1165
pubmed: 31177874
Clin Breast Cancer. 2008 Feb;8(1):88-91
pubmed: 18501063
Sleep Med Rev. 2021 Apr;56:101409
pubmed: 33333427
Perspect Psychol Sci. 2015 Jan;10(1):97-137
pubmed: 25620997
Breast Cancer Res Treat. 2008 Jul;110(1):143-52
pubmed: 17674194
Springerplus. 2014 Aug 19;3:444
pubmed: 25184110
Sleep. 2011 May 01;34(5):601-8
pubmed: 21532953
Sleep Med. 2019 Mar;55:14-21
pubmed: 30743205
Neurosci Biobehav Rev. 2018 Jan;84:35-48
pubmed: 29032088
Hippocampus. 2020 Aug;30(8):794-805
pubmed: 31743543
J Neurosci. 2002 Dec 15;22(24):10941-7
pubmed: 12486189
Curr Biol. 2022 Jun 6;32(11):2349-2356.e4
pubmed: 35561681
Front Physiol. 2019 Nov 20;10:1396
pubmed: 31824327
Breast Cancer. 2020 Sep;27(5):893-902
pubmed: 32301096
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
Support Care Cancer. 2012 Dec;20(12):3297-305
pubmed: 22549504
Sleep. 2022 Apr 11;45(4):
pubmed: 34624895
J Formos Med Assoc. 2006 Jan;105(1):64-9
pubmed: 16440072
Cancer. 2007 Jan 1;109(1):146-56
pubmed: 17131349
Neuropsychiatr Dis Treat. 2014 Jun 18;10:1113-24
pubmed: 24971014
Breast. 2014 Dec;23(6):697-709
pubmed: 25307946
Biomolecules. 2021 Mar 24;11(4):
pubmed: 33804974
J Cancer Surviv. 2012 Mar;6(1):11-9
pubmed: 22160661
Support Care Cancer. 2006 Mar;14(3):201-9
pubmed: 16010529
Sci Rep. 2019 Jun 27;9(1):9310
pubmed: 31249334
Front Oncol. 2022 Oct 28;12:1009064
pubmed: 36387255
Psychoneuroendocrinology. 2017 Sep;83:25-41
pubmed: 28578301
Behav Sleep Med. 2013;11(4):239-57
pubmed: 23181706
Int J Chronobiol. 1976;4(2):97-110
pubmed: 1027738
Psychooncology. 2018 Mar;27(3):802-809
pubmed: 29055062
J Clin Oncol. 1993 Mar;11(3):570-9
pubmed: 8445433
Rev Neurol (Paris). 2006 Jun;162(6-7):721-8
pubmed: 16840980
Health Qual Life Outcomes. 2003 Dec 16;1:79
pubmed: 14678568
Sleep. 2009 Sep;32(9):1155-60
pubmed: 19750920
Nat Sci Sleep. 2012 Dec 17;4:151-162
pubmed: 23486503
Support Care Cancer. 2010 Jun;18(6):679-89
pubmed: 19521723
Acta Neurol Belg. 1990;90(4):207-17
pubmed: 2124031
Breast Cancer Res Treat. 2006 Aug;98(3):343-8
pubmed: 16541322
Chronobiol Int. 2020 Jun;37(6):946-951
pubmed: 32326769
Hum Brain Mapp. 2012 Dec;33(12):2971-83
pubmed: 22095746
J Clin Oncol. 2011 Sep 10;29(26):3580-6
pubmed: 21825267
CA Cancer J Clin. 2015 Mar;65(2):123-38
pubmed: 25483452
Breast. 2017 Dec;36:96-101
pubmed: 28668292
Ann Intern Med. 1999 Oct 5;131(7):485-91
pubmed: 10507956
Int Rev Psychiatry. 2014 Feb;26(1):102-13
pubmed: 24716504
J Psychosom Res. 2011 Dec;71(6):423-8
pubmed: 22118386
Neuroscience. 2019 Mar 15;402:104-115
pubmed: 30615913
Neurobiol Sleep Circadian Rhythms. 2018 Mar 01;5:68-77
pubmed: 31236513
Neuropsychol Rev. 2020 Sep;30(3):287-309
pubmed: 32607817
Sleep. 2019 Mar 1;42(3):
pubmed: 30521041
J BUON. 2019 Mar-Apr;24(2):529-534
pubmed: 31128001
Fatigue. 2013;1(1-2):12-26
pubmed: 23412418
J Clin Oncol. 2012 Apr 1;30(10):1080-6
pubmed: 22370315
Oncologist. 2019 Jan;24(1):62-68
pubmed: 29934409
J Clin Oncol. 2008 May 20;26(15):2464-72
pubmed: 18487566
Support Care Cancer. 2022 Apr;30(4):3187-3200
pubmed: 34957532
Psychoneuroendocrinology. 2004 Sep;29(8):1082-92
pubmed: 15219660
Breast Cancer Res Treat. 2019 Jul;176(1):1-15
pubmed: 30955185